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Abstract
Epigenetic marks like methylation of cytosines at CpG dinucleotides are essential for mammalian development and play
a major role in the regulation of gene expression and chromatin architecture. The methyl-cytosine binding domain (MBD)
protein family recognizes and translates this methylation mark. We have recently shown that the level of MeCP2 and MBD2,
two members of the MBD family, increased during differentiation and their ectopic expression induced heterochromatin
clustering in vivo. As oligomerization of these MBD proteins could constitute a factor contributing to the chromatin
clustering effect, we addressed potential associations among the MBD family performing a series of different interaction
assays in vitro as well as in vivo. Using recombinant purified MBDs we found that MeCP2 and MBD2 showed the stronger
self and cross association as compared to the other family members. Besides demonstrating that these homo- and hetero-
interactions occur in the absence of DNA, we could confirm them in mammalian cells using co-immunoprecipitation
analysis. Employing a modified form of the fluorescent two-hybrid protein-protein interaction assay, we could clearly
visualize these associations in single cells in vivo. Deletion analysis indicated that the region of MeCP2 comprising amino
acids 163–309 as well the first 152 amino acids of MBD2 are the domains responsible for MeCP2 and MBD2 associations. Our
results strengthen the possibility that MeCP2 and MBD2 direct interactions could crosslink chromatin fibers and therefore
give novel insight into the molecular mechanism of MBD mediated global heterochromatin architecture.
Citation: Becker A, Allmann L, Hofsta¨tter M, Casa` V, Weber P, et al. (2013) Direct Homo- and Hetero-Interactions of MeCP2 and MBD2. PLoS ONE 8(1): e53730.
doi:10.1371/journal.pone.0053730
Editor: Pierre-Antoine Defossez, Universite´ Paris-Diderot, France
Received September 3, 2012; Accepted December 4, 2012; Published January 15, 2013
Copyright:  2013 Becker et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was funded by grants of the Deutsche Forschungsgemeinschaft [DFG SPP 1356 and 1129] (URL: www.dfg.de) and the Bundesministerium fu¨r
Forschung und Technik BMBF [02S8355] (URL: www.bmbf.de). The funders had no role in study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: cardoso@bio.tu-darmstadt.de
. These authors contributed equally to this work.
Introduction
The epigenetic information in mammals is encoded in the form
of methylated cytosines at the C5 position within CpG dinucleo-
tides and modifications of histone tails among many others.
Methylated CpGs (mCpGs) are recognized by methyl-cytosine
binding proteins like Kaiso proteins, SRA domain containing
proteins and methyl-cytosine binding domain (MBD) proteins [1].
They read this epigenetic DNA mark and translate it into higher-
order chromatin structures and therefore form an important link
between DNA methylation and chromatin organization.
MBD1, MBD2, MBD3, MBD4 and MeCP2 represent the most
studied members of the MBD protein family [2]. They all bear
a conserved MBD domain that enables them, except for MBD3, to
bind to mCpGs [3–6] leading to their predominant accumulation
at constitutive heterochromatin in vivo [4,7].
MeCP2 was originally described as a transcriptional regulator
imposing local repressive chromatin structures through recruit-
ment of histone-modifying enzymatic activities [8–15]. Recent
reports further implicate the intrinsic capability of MeCP2 to
organize global heterochromatin architecture [7,16,17]. We have
shown that MeCP2 induces large-scale chromatin reorganization
in vivo - in particular clustering of pericentric heterochromatin - in
a dose-dependent manner [7]. The MBD was shown to be
necessary and sufficient for MeCP2 chromatin aggregation ability,
and a MeCP2 deletion construct lacking the NH2-terminal region
and the MBD is insufficient to induce clustering of chromatin
in vivo [7]. Mutations within theMECP2 gene have been linked to
the neurological disease Rett Syndrome [18,19]. We recently
tested several missense mutations within MeCP2 MBD and found
that they affect MeCP2 ability to accumulate at pericentric
heterochromatin and/or cluster heterochromatin in vivo [20,21].
In line with the role of MeCP2 in pericentric chromatin
clustering in vivo, in vitro assays demonstrated that MeCP2 can
compact polynucleosomes into highly condensed suprastructures
[16,22]. Nucleosome interaction studies indicated that mostly
residues in the COOH-terminal regions of MeCP2 are involved in
chromatin binding [22,23]. Importantly, maximal compaction of
nucleosomal arrays involving secondary and tertiary chromatin
structures does not take place in the absence of the region COOH-
terminal from the MBD [16].
As a potential mechanism underlying MeCP2 coordination of
global chromatin architecture, a sandwich-like formation of
MeCP2 with nucleosomes and/or DNA has been proposed, most
probably requiring at least two chromatin or DNA binding sites
within MeCP2 [16,22]. Oligomerization of MeCP2, resulting in
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nucleosome-MeCP2-MeCP2-nucleosome or DNA-MeCP2-
MeCP2-DNA complexes, has also been proposed [7,16]. The
fact that MeCP2 induces different levels of chromatin structure
in vitro depending on the ratio of MeCP2 to nucleosomes, together
with the in vivo findings that increasing level of MeCP2 results in
increased heterochromatin aggregation strengthen this hypothesis
[7,16]. Recent studies illustrated inter-domain associations of
certain domains of MeCP2 in trans using fluorescence anisotropy
and circular dichroism [24]. Furthermore, using atomic force
microscopy, MeCP2 has been shown to exist as a monomer and
dimer on DNA [25]. However, hydrodynamic studies describing
recombinant MeCP2 as a monomer have challenged oligomeri-
zation of MeCP2 [26,27]. We therefore assayed potential
interactions of MeCP2 with itself as well as other members of
the MBD protein family that could be involved in crosslinking
heterochromatin fibers. Using in vitro pull-down experiments, we
show that MeCP2 indeed forms direct homo-interactions with
itself and hetero-associations to MBD2. We further mapped the
interacting domains and found one defined region of MeCP2 and
of MBD2 mediating both, binding to MeCP2 and MBD2. Finally,
we could confirm these associations in vivo using different
interaction assays.
Materials and Methods
Expression Plasmids
Mammalian expression vectors for rat MeCP2G, MeCP2R and
GBP-laminB were described before [7,28].
MeCP2R was used to create the vector pmRFP-N2 by replacing
EGFP from pEGFP-N2 (Clontech; Mountain View, CA, USA)
with mRFP using BamHI and BsrGI.
Mouse MBD2 tagged with GFP (MBD2G) was created by
replacing EGFP from pEGFP-N1 (Clontech; Mountain View, CA,
USA) with the MBD2-GFP fragment from the pFastBac vector
MBD2aG (described below) using EcoRI and BsrGI.
MBD2 tagged with RFP (MBD2R) was created by subcloning
MBD2 from the pFastBac vector MBD2aG with EcoRI and NotI
into pBluescript KS+ (Stratagene; Agilent Technologies Geno-
mics, Santa Clara, CA, USA) cut with EcoRI and PspOMI.
MBD2 was then transferred into pmRFP-N2 using EcoRI and
KpnI digestion.
To produce pMeCP2R.9, pMeCP2G.9 [29] was digested with
BamHI and NheI releasing the MeCP2.9 fragment. The insert was
then ligated into pmRFP-N2 vector, cut before with the same
restriction sites.
pMBD2R.1 for expression in mammalian cells was created by
cloning the EcoRI/NotI fragment of pFB-MBD2R.1 into pEGFP-
N1, thereby replacing EGFP by cutting with the same enzymes.
For expression in Sf9 cells (Invitrogen; Paisley PA4 9RF, UK)
the Bac-To-Bac baculovirus expression system (Invitrogen; Paisley
PA4 9RF, UK) was used. Full length MeCP2 constructs tagged
with GFP (MeCP2G) and strep (stMeCP2) were described before
[29].
For construction of MeCP2 tagged with mRFP (MeCP2R),
GFP was replaced from the pFastBac vector MeCP2G by mRFP
using PspOMI and XhoI sites. Vectors for GFP expression, pFB-
C-GFP and pFB-C-GFP octa, were created by amplification of
GFP from pEGFP-C1 (Clontech; Mountain View, CA, USA) with
NotI and XbaI sites and cloned into pFastBac-1 (Invitrogen;
Paisley PA4 9RF, UK). AsiSI and NotI sites were introduced by
oligo cloning resulting in pFB-C-GFP-octa.
For mRFP expression, pFB-mRFP was created by cloning the
EcoRI-NotI fragment from pmRFP-N2 into pFastBac-1.
Mouse MBD1a, MBD2a, MBD3 and MBD4 tagged with GFP
were created by amplification from already described mammalian
expression constructs [4] with primers including SalI and NotI
sites and cloned into pFB-C-GFP. Strep-tagged MBD2 (MBD2st)
was created by replacing GFP from MBD2G with a strep-tag [29],
amplified using primers flanked by NotI and XhoI sites.
MBD2 tagged with mRFP (MBD2R) was taken from the
mammalian expression vector using EcoRI and NotI and cloned
into pFastBac-1.
The MeCP2 deletion constructs MeCP2Y.3 (aa 1–162) and
MeCP2Y.5 (aa 77–162) were created from mammalian expression
vectors described before [7] by cloning the NotI or BamHI-NotI
fragment into pFastBac-1, respectively.
MeCP2G.8 (aa 310–492) and MeCP2G.9 were amplified from
mammalian expression vector pMeCP2G.6 [30] with primers
including BglII and NotI or BamHI and NotI sites, respectively.
MeCP2G.8 BglII-NotI fragment was ligated into BamHI and NotI
sites in pFastBac-1. MeCP2.9 BamHI-NotI fragment was ligated
into pFB-C-GFP cut with same enzymes. For mCherry-tagged
MeCP2.9, GFP was replaced with mCherry by ligating PspOMI-
mCherry-XbaI fragment with pFB-MeCP2G.9 cut with NotI and
XbaI resulting in MeCP2Ch.9.
MeCP2G.10 was custom synthesized into pCR4-TOPO (In-
vitrogen; Paisley PA4 9RF, UK) flanked by SalI and NotI sites
(Entelechon; Bad Abbach, Germany). The fragment was ligated
into pFB-C-GFP, cut with the same sites.
MBD2 deletion constructs MBD2.1 (aa 1–152) and MBD2.2 (aa
153–414) were amplified from pFB-MBD2a-C-GFP (MBD2G)
with forward primers carrying AsiSI sites and reverse primers with
NotI sites. Digested fragments were ligated into pFB-C-GFP octa
cut with the same enzymes. For generation of RFP-tagged
MBD2.1, pFB-MBD2G.1 was digested with EcoRI and NotI
and the fragment was ligated into pFB-mRFP cut with EcoRI and
PspOMI. MBD2.3 (aa 222–414) and MBD2.4 (aa 236–414) were
amplified from pFB-MBD2G.2 with forward primers coding for
SalI and reverse primers keeping the existing NotI restrictions sites
and then cloned into pFB-C-GFP octa. GFP was then replaced by
mcherry.MBD2.5 (aa 153–221) was synthesized (in pMK-RQ;
GeneArt; Invitrogen; Paisley PA4 9RF, UK) flanked by EcoRI
and PspOMI sites and cloned into pFB-mRFP resulting in
MBD2R.5. MBD2.6 (aa 153–235) was synthesized (in pMK-
RQ; GeneArt; Invitrogen; Paisley PA4 9RF, UK) flanked by SalI
and NcoI and cloned into pFB-C-GFP octa. GFP was then
replaced by mRFP from pFB-mRFP using AgeI and XhoI to
create MBD2R.6.
Cell Culture, Transfection and Staining
HEK 293-EBNA cells (Invitrogen; Paisley PA4 9RF, UK) were
cultured and transfected as described [30].
C2C12 mouse myoblasts [31] were grown at 37uC and 5% CO2
in Dulbecco’s Modified Eagle Medium (DMEM) supplemented
with 20% fetal calf serum. Cells were grown to 70% confluency on
16 mm glass cover slips in 6 well plates and transfected using poly-
ethylenimine (PEI, 1 mg/ml in ddH2O, pH 10; Sigma-Aldrich,
St. Louis, MO, USA) [21]. One day after transfection, the cells
were fixed using a formaldehyde (FA) gradient as described before
[21]. After fixation, cells were mounted in Vectashield antifade
medium (Vector Laboratories, Burlingame, CA, USA).
Sf9 insect cells (Invitrogen; Paisley PA4 9RF, UK) were
cultivated in EX-CELL 420 Insect Serum Free (SAFC) medium
supplemented with 10% fetal calf serum. The culture was kept
shaking at 100 rpm and 28uC. Transfection of Sf9 cells to produce
recombinant baculovirus was performed using Cellfectin (Invitro-
gen; Paisley PA4 9RF, UK) according to the manufacturer’s
MeCP2 and MBD2 Interactions
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instructions. For protein production, Sf9 insect cells were infected
with the recombinant baculovirus (P3 stock) and incubated for 5
days shaking at 28uC. The cells were pelleted by centrifugation
(2006g, 5 min, 4uC).
Fluorescent 3-hybrid Assay
Fixed C2C12 cells were examined with a Zeiss Axioplan2 wide-
field epifluorescence microscope. To quantify the % of cells
displaying co-localization, 100 cells were analyzed per trans-
fection. Image stacks (0.6 mm Z interval) were acquired using
a 636Plan-Apochromatic NA 1.4 oil immersion phase contrast
objective lens and a PCO Sensicam QE cooled CCD camera.
In vivo Co-immunoprecipitation Assays
For co-immunoprecipitation analysis of full-length MBD
proteins, HEK 293-EBNA cells (p100 dish) co-transfected with
GFP- and RFP- fused MBD proteins or GFP control were pelleted
after washing with 16PBS and resuspended in 200 ml 46PBS and
incubated on ice for 5 min. For efficient lysis, incubation was
followed by a short syringe treatment (2–3 times) and subsequent
dilution of the lysate with 600 ml buffer A (20 mM Tris-HCl pH 8,
0.5% NP-40, 0.5 mM EDTA) to obtain a NaCl concentration of
137 mM or 200 ml buffer A for a final concentration of 274 mM
NaCl. After incubation for 15 min on ice and centrifugation at
20.0006g for 12 min at 4uC, the lysate was incubated with GFP
binding protein (GBP) coupled to sepharose beads (GFP-Trap,
ChromoTek, Planegg-Martinsried, Germany; [28]) for one hour at
4uC on a rotary shaker. Afterwards, the beads were washed three
Figure 1. Interactions amongMBD proteins. (A) Upper panel: schematic representation of methyl-cytosine binding domain (MBD) proteins. The
numbers stand for amino acid coordinates. (MBD) methyl-cytosine binding domain, (TRD) transcriptional repression domain, (CxxC) cysteine rich
domain. Lower panel: In vitro pull down experiments using purified strep (st) fused MeCP2 or MBD2 and GFP-labeled full-length (fl) MBD proteins
immobilized to GFP-binding protein (GBP) bound sepharose beads. The proteins were extracted using 0.5 M NaCl containing lysis buffer. The
interaction assays were performed either in PBS supplemented with 0.05% NP-40 (stMeCP2) or in PBS plus 150 mM NaCl and 0.05% NP-40 (MBD2st).
Interacting st-taged fl MeCP2 and MBD2 were assessed by Western blot using st-HRP conjugate. Coomassie Brilliant Blue (CBB) staining of the SDS-gel
after protein transfer shows GFP-labeled immobilized MBD proteins used for the pull-down assay. (B, C, D) Interactions between MeCP2 and MBD2
are not bridged by DNA. In vitro pull-down experiments were performed using immobilized RFP-fused MeCP2 (MeCP2R) or MBD2 (MBD2R) and GFP-
labeled MeCP2 (MeCP2G) or MBD2 (MBD2G) either with or without addition of ethidium bromide (EtBr; 10 mg/ml). All proteins were extracted in 1 M
NaCl containing lysis buffer. In the case of MeCP2 homo-interactions (B), the interaction was performed in PBS plus 0.05% NP-40 buffer. For the
homo-interactions of MBD2 (C), PBS was additionally supplemented with 110 mM NaCl and 0.05% NP-40, and for the hetero-binding of MBD2 and
MeCP2 (D), PBS plus 125 mM NaCl and 0.05% NP-40 was used. (B, C, D) For input control (I),J of the protein amount used for the interaction assay
of the immobilized RFP-tagged proteins was loaded on SDS-PAGE and stained with CBB. AlsoJ of the GFP-tagged proteins used for the pull-down
were visualized by western blot using anti GFP (I). Interacting GFP-fused MeCP2 or MBD2 (B) were assessed by western blot using anti GFP antibody.
doi:10.1371/journal.pone.0053730.g001
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times with 300 ml buffer B1 (20 mM Tris-HCl pH 7.5, 200 mM
NaCl, 0.5% NP-40, 0.5 mM EDTA) or buffer B2 (20 mM Tris-
HCl pH 8, 275 mM NaCl, 0.5 mM EDTA, 0.1% NP-40) and
then resuspended in 30 ml 16SDS-containing sample buffer and
boiled for 6 min at 99uC to be analyzed by SDS-PAGE followed
by Western Blot. For co-immunoprecipitation analysis of domains
of the MBD proteins, HEK 293-EBNA cells were co-transfected
with plasmids coding for RFP- and GFP-labeled domains of the
MBD protein or GFP control. The co-transfected cells were lysed
using buffer A (20 mM Tris-HCl pH 8, 0.5% NP-40, 0.5 mM
EDTA) supplemented with 200 mM NaCl. After syringe treat-
ment (2–3 times), the lysate was incubated on ice for 15 min
followed by centrifugation at 20.0006g for 12 min at 4uC.
Afterwards, the lysate was incubated for one hour at 4uC together
with GBP-coupled sepharose beads. The immobilized protein
complexes were washed with buffer A supplemented either with
200 mM NaCl or 300 mM NaCl and resuspended in 40 ml
16SDS-containing sample buffer and boiled for 6 min at 99uC to
be analyzed by SDS-PAGE followed by Western Blot. All buffers
were supplied with protease inhibitors in following concentrations:
AEBSF 1 mM (AppliChem; Darmstadt, Germany), Leupeptin
1 mM (Sigma-Aldrich, St. Louis, MO, USA), Pepstatin A 1 nM
(Sigma-Aldrich, St. Louis, MO, USA) and Aprotinin 2 ng/ml
(Sigma-Aldrich, St. Louis, MO, USA).
In vitro Binding Assays
Sf9 cells overexpressing the protein of interest were resuspended
in buffer C (25 mM Tris-HCl, pH 8.0, 1 M NaCl, 50 mM
glucose, 10 mM EDTA, 0.2% Tween-20, 0.2% NP-40) or D
(25 mM Tris-HCl, pH 7.5, 500 mM NaCl, 5% Glycerol, 0.2%
Figure 2. Homo and hetero-interactions of MeCP2 and MBD2 in vivo. (A, B, C) GFP alone and GFP- and RFP-tagged MeCP2 and MBD2 were
co-expressed in HEK293-EBNA cells as indicated. After extraction, co-immunoprecipitation assays were performed at 137 mM (A) or 274 mM (B and
C) NaCl using GBP-bound beads. The bound fraction (B) of the immobilized proteins used for the interaction assay was visualized by western blot
using anti GFP antibody. The input (I) and bound fraction (B) of the interacting RFP-labelled proteins were visualized using anti RFP antibody. The
input (I) represents 3.75% (A) and 7.5% (B and C) of the total reaction volume. (A) Homo-interactions of MeCP2, (B) binding of MBD2 to itself and (C)
hetero-interactions of MeCP2 and MBD2. (D, E, F) C2C12 mouse cells were transfected with plasmids coding for (D) RFP and GFP-fused MeCP2, (E)
RFP-fused MeCP2 or MBD2, GFP control and a protein fusion of the GFP binding protein (GBP) and lamin B1 (GBP-laminB1), (F) two fluorescently
labeled methyl-cytosine binding domain (MBD) proteins as indicated and GBP-laminB1. Shown are representative images of mouse cells expressing
the proteins as indicated. Scale bar: 5 mm. The graphs represent % of cells with co-localization of the fluorescent signals. The experiment was
repeated twice, analyzing 100 cells (n = 100) each time. Right side: Schematic illustrations of the interaction assay. (D, right side) Localization of RFP-
and GFP-fused MeCP2 proteins at pericentric heterochromatin in mouse cells. (E, right side) Mouse cell expressing RFP-labelled MBD protein, GFP
control and GBP-laminB1. Due to GBP-laminB1, GFP is recruited at the lamina. The RFP-MBD protein is localized to heterochromatin. (F, right side)
Mouse cells expressing GFP and RFP-tagged MBD proteins and GBP-laminB1. In case of an interaction between both fluorescently labeled MBDs, the
RFP and GFP signals co-localize. G and R stand for GFP and RFP respectively.
doi:10.1371/journal.pone.0053730.g002
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Triton X-100). All buffers used for the in vitro assays were
supplemented with the protease inhibitors AEBSF, Leupeptin,
Pepstatin and Aprotinin in the concentrations as described above.
After incubation on ice for 10 min, cells were disrupted by
sonification. After centrifugation (20.0006g, 4uC) for 30 min, the
supernatant was removed from the cell debris and used for the
next steps. The GFP or RFP- fused proteins were immobilized to
GBP or RFP binding protein (RBP) coupled to sepharose beads
(GFP-Trap, RFP-Trap, ChromoTek, Planegg-Martinsried, Ger-
many) [28,32] by incubation at 4uC for 30 min. Afterwards, the
immobilized proteins were washed three times with buffer C or D
followed by two washes using the interaction buffer E (PBS, 0.05%
NP-40) with varying amount of NaCl as indicated in the legends to
each figure.
Purification of strep-tagged recombinant proteins was achieved
by incubating the protein extract with 500 ml of Strep-Tactin
Sepharose (IBA GmbH; Goettingen, Germany) beads for three
hours at 4uC on a rotary shaker. For elution of the strep-tagged
proteins, the beads were incubated with D-Desthiobiotin (0.5 mg/
ml; IBA), dissolved in 1x PBS, for 30 min at 4uC. After
centrifugation (2006g, 2 min), beads were separated from the
eluate containing the purified proteins. The first two eluates were
pooled and used for the assay.
For in vitro binding assays, immobilized recombinant GFP- or
RFP- tagged proteins as indicated were incubated with nearly
equal amounts of purified proteins or protein extracts in 500 ml
buffer E for one hour at 4uC on a rotary shaker. After a short spin,
the beads were washed three times with buffer E, dissolved in
40 ml 16SDS-containing sample buffer and boiled for 10 min at
99uC.
Western Blot Analysis
Western blotting was performed as described before [33]
transferring the proteins on a nitrocellulose membrane (GE
Healthcare, Mu¨nchen, Germany). Visualization of the immuno-
reactive bands was achieved by ECL plus Western Blot Detection
reagent (GE Healthcare; Mu¨nchen, Germany). The following
antibodies were used: rat monoclonal anti GFP 3H9 (ChromoTek,
Planegg-Martinsried, Germany), rabbit polyclonal anti RFP,
mouse monoclonal anti GFP (Roche; Mannheim, Germany) and
rat monoclonal anti RFP 5F8 [34] (ChromoTek, Planegg-
Martinsried, Germany). Horseradish peroxidase conjugated
(HRP) anti mouse IgG (GE Healthcare; Mu¨nchen, Germany),
HRP conjugated goat anti rat IgG (Jackson; West Grove, PA,
USA) and HRP conjugated anti rabbit IgG (Sigma-Aldrich, St.
Louis, MO, USA) were used as secondary antibodies. To detect
strep-fused proteins, the membrane was incubated with horserad-
ish peroxidase conjugated StrepTactin (Bio-Rad Laboratories,
Hercules, CA, USA) for 1.5 hours at room temperature.
Results and Discussion
MBD2 and MeCP2 Exhibit the Strongest Interactions
among all MBD Proteins
Based on our recent observations that ectopic expression of
MeCP2 induces clustering of pericentric heterochromatin in vivo
[7], we hypothesized that MeCP2 could potentially interact with
itself and accomplish the chromatin aggregation process not only
as a monomer, but also as di- or oligomer. Besides MeCP2-
MeCP2 homo-interactions, also MeCP2 hetero-interactions to
other MBD family members could be an additional factor
contributing to MeCP2 mediated large-scale heterochromatin
organization.
For this reason, we set out to analyze interactions of MeCP2
with itself and other members of the MBD protein family and
performed in vitro pull down experiments using recombinant
proteins produced in Sf9 insect cells. Immobilized GFP-tagged
MeCP2 (MeCP2G), MBD1 (MBD1G), MBD2 (MBD2G), MBD4
(MBD4G) and GFP alone were incubated with full-length strep-
fused MeCP2 (stMeCP2). SDS-PAGE followed by western blot
analysis using strep-HRP (st-HRP) conjugate revealed that
stMeCP2 exhibited binding to itself as well as MBD2G, but not
to MBD1G, MBD4G and GFP (Figure 1A and Figure S1A).
Prompted by the result, that stMeCP2 strongly interacted with
MBD2G, we went on analyzing the binding ability of strep-fused
MBD2 (MBD2st) to itself as well as to MeCP2G, MBD1G,
MBD4G and GFP. Whereas GFP alone, MBD1G and MBD4G
showed very weak to no binding to MBD2st, MBD2G as well as
MeCP2G again exhibited the strongest association to MBD2st
(Figure 1A and Figure S1A). These results indicated that MeCP2
had the strongest binding affinity to itself and MBD2 and vice
versa MBD2 exhibited the most prominent associations to itself
and MeCP2.
We excluded MBD3 from our interaction studies and did not
check for MeCP2 and MBD2 binding to MBD3, as MBD3 has
been reported to be unable to bind to methylated DNA [4–6] and
unable to exhibit strong accumulation at pericentric heterochro-
matin. We therefore ruled out that MBD3 could contribute to the
aggregation of pericentric heterochromatin.
With the salt conditions (500 mM NaCl containing lysis buffer),
used to extract the proteins from the cells for the in vitro pull down
assays, one could not exclude that the observed interactions might
be bridged to some extent by DNA. For that reason, we repeated
the observed MeCP2 and MBD2 homo- and hetero-interactions
this time using 1 M NaCl containing lysis buffer for the extraction
of the proteins plus addition of ethidium bromide (EtBr) to disrupt
potential protein-DNA interactions [35]. Incubation of recombi-
nant RFP-tagged MeCP2 (MeCP2R) or RFP alone immobilized
to sepharose-beads with GFP-fused full-length MeCP2 (MeCP2G)
Figure 3. Mapping of domains responsible for MeCP2 and MBD2 homo- and hetero-interactions. (A) In vitro pull-down experiments
with immobilized YFP- or GFP-fused MeCP2 constructs as illustrated and full-length (fl) RFP-labelled MeCP2 (MeCP2R) and MBD2 (MBD2R). The
interactions were performed in PBS buffer supplemented with 125 mM NaCl and 0.05% NP-40. Interacting RFP-tagged proteins (B) were assessed by
western blot with anti-RFP and Coomassie Brilliant Blue (CBB) staining of the gel after protein transfer was performed to visualize the immobilized
YFP- or GFP-fused constructs (B). For input control (I), J of the protein amounts used for the interaction assay was taken and stained by CBB or
western blot using anti RFP. (B) Pull-down experiments using Cherry- (Ch) or RFP-fused MBD2 constructs as indicated, immobilized to RFP-binding
protein (RBP) bound sepharose beads, and GFP-labelled fl MBD2 (MBD2G) and MeCP2 (MeCP2G). The assays were performed in PBS supplemented
with 125 mM NaCl and 0.05% NP-40. The interacting proteins (B) were analyzed by western blot with anti GFP and CBB staining of the gel after
protein transfer for the immobilized Cherry- or RFP-fused MBD2 constructs (B). As for (A), J of the protein amounts used for the interaction assay
were loaded as input control (I) and visualized either by western blotting with anti GFP or CBB respectively. (C) In vitro binding assays using YFP- or
GFP-labelled MeCP2 or MBD2 constructs as indicated, immobilized to GFP-binding protein (GBP) bound beads, and RFP-fused MBD2 NH2-terminal
domain (NTD) and Cherry-fused MeCP2 ID-TRD. The interaction was performed in PBS supplemented with 125 mM NaCl and 0.05% NP-40. Interacting
Cherry- or RFP-tagged proteins (B) were assessed by western blot with anti RFP and Coomassie Brilliant Blue (CBB) staining of the gel after protein
transfer was performed to visualize the immobilized YFP- or GFP-fused constructs (B).J of the protein amounts used for the interaction assay were
loaded as input control (I) and visualized either by western blotting with anti RFP or CBB. G, R and Ch stand for GFP, RFP and Cherry respectively.
doi:10.1371/journal.pone.0053730.g003
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again showed a clear binding of MeCP2G to RFP-labelled MeCP2
but not to the RFP control (Figure 1B and Figure S1B). The
specific MeCP2 homo-interaction could also be detected upon
addition of ethidium bromide (EtBr), underlining that the observed
direct binding was independent from DNA bridging (Figure 1B).
Furthermore, we could detect specific binding of MBD2G to
immobilized RFP-fused MBD2 (MBD2R) (Figure 1C and Figure
S1B) as well as of MeCP2G to immobilized MBD2R (Figure 1D
and Figure S1B) without and upon addition of EtBr.
Although hydrodynamic studies claimed that recombinant
MeCP2 has the properties of a monomer [26,27], the outcome
of our in vitro pull down analyses showed that MeCP2 does directly
interact with itself in the absence of DNA. These findings are in
line with recent reports describing the formation of monomeric
and dimeric foci of MeCP2 when bound to DNA [25]. We also
show clear direct hetero-binding of MeCP2 with MBD2 as well as
homo-interactions of MBD2 to itself, giving support to the
hypothesis that MeCP2 and MBD2 homo- as well as hetero-
Figure 4. In vivo homo- and hetero-interactions between domains of MeCP2 and MBD2. (A) GFP- and RFP-tagged domains of MeCP2 and
MBD2 as well as GFP control were co-expressed in HEK293-EBNA cells as indicated. After cell lysis using 200 mM NaCl buffer conditions, the extract
was incubated with GBP-bound beads for co-immunoprecipitation analysis under the same buffer conditions. The immobilized protein complexes
were washed afterwards with the same buffer as used for lysis and co-immunoprecipitation. The immobilized GFP-labeled proteins (B) used for the
interaction assay were visualized by western blot using anti GFP antibody. The input (I) and the co-immunoprecipitated fraction (B) of the RFP-labeled
proteins were visualized through western blot using anti RFP antibody. The input (I) represents 7% of the total reaction volume. (B and C) Schematic
representation of the domains responsible for the homo-and hetero-interactions of MeCP2 and MBD2 (dark grey) illustrating the outcome of the
in vivo and in vitro interaction analyses. Numbers stand for amino acid (aa) coordinates. (C) Full-length (fl) MeCP2 and MBD2 directly bind to
themselves and each other (green). In case of the MeCP2 homo-interaction, the ID-TRD (aa 163–309) is the domain of MeCP2 that mediates strong
direct binding to fl MeCP2 (light grey) and further recognizes the ID-TRD domain independently (dark grey). Regarding MeCP2 and MBD2 hetero-
interaction, MeCP2 ID-TRD domain exhibits strong association to fl MBD2 in comparison to other MeCP2 domains (light grey) and further directly and
independently interacts to the NH2-terminal domain (NTD, aa 1–152) of MBD2 (dark grey). The NTD is also the only domain of MBD2 that shows
strong binding to fl MeCP2 (light grey) and strongly binds to MeCP2 ID-TRD independently (dark grey). In the case of the MBD2 homo-interaction, the
NTD is again the region of MBD2 exerting the strongest binding to fl MBD2 (light grey) and further recognizes MBD2 NTD and COOH-terminal domain
(dark grey).
doi:10.1371/journal.pone.0053730.g004
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interactions could indeed constitute one additional factor contrib-
uting to the clustering of pericentric heterochromatin in vivo.
MeCP2 and MBD2 form Homo- and Hetero-interactions
in vivo
To test, whether the observed interactions could be detected in
mammalian cells, we co-transfected HEK 293 cells with plasmids
coding for RFP- and GFP-fused MeCP2 as well as MeCP2R and
GFP alone. The cells were lysed and the cell extract was subjected
to immunoprecipitation using anti GFP antibody. After separation
of the probes through SDS-PAGE, western blot analysis using anti
RFP antibody showed that MeCP2R bound to MeCP2G but not
to the GFP control (Figure 2A and Figure S2). The same
procedure was repeated by co-transfection of HEK-293 cells with
RFP- and GFP-fused MBD2 as well as MBD2R and MeCP2G
and clearly indicated that MBD2 homo- and MBD2-MeCP2
hetero-interactions were observed in mammalian cells (Figure 2B
and C and Figure S2).
In a next step, we aimed to visualize the observed in vivo
interactions in single cells in vivo. For that reason we made use of
a modified form of the fluorescent two-hybrid assay [36]. Instead
of tethering the fluorescent MeCP2 or MBD2 protein to
a chromosomal lac operator array, we artificially tethered GFP-
labelled MeCP2 or MBD2 to the nuclear lamina. This was
achieved by co-transfection of mouse C2C12 cells with plasmids
coding for the GFP tagged MBD protein or GFP control alone
and a fusion of the GFP binding protein (GBP) and lamin B1 [28].
Through this cellular nanotrap at the nuclear lamina, GFP or GFP
fused proteins get recognized and bound by the GBP tethered to
the lamina and get therefore additionally recruited to the lamina
[28]. In the case of a triple transfection of the cells with plasmids
coding for the fusion of GBP and lamin B1 (GBP-laminB1), a GFP-
labelled bait and a RFP-fused prey protein, the bait is targeted to
the lamina through its binding to GBP-laminB1. An interaction
between the GFP-tagged bait and the RFP-fused prey and
therefore the additional recruitment of the prey to the lamina
can get visualized through co-localization of the GFP and RFP
fluorescent signals (Figure 2E and F).
To exclude any binding of the two fluorescent tags with each
other as well as recruitment of RFP-fused MeCP2 and/or MBD2
to the lamina, we triple transfected mouse cells with plasmids
encoding GBP-laminB1, GFP control and RFP fused MeCP2 or
MBD2 (Figure 2E). Whereas GFP alone was almost equally
distributed along the lamina through its binding to GBP-laminB1,
no co-localization of the RFP and GFP fluorescent signals was
detectable, ruling out any binding of MeCP2R or MBD2R to the
lamina or of RFP to the lamina, GFP alone or GBP-laminB1
(Figure 2E). The RFP- labeled MBD proteins further showed their
expected localization to pericentric heterochromatin, comparable
to mouse cells expressing MBD proteins in the absence of GBP-
laminB1 (Figure 2D).
In a next step we wanted to examine, whether we could observe
in vivo homo-interactions of MeCP2 in single cells using this
method. Triple transfection of mouse cells with GBP-laminB1,
MeCP2G and MeCP2R resulted in clear co-localization of both
fluorescent proteins at several stretches along the lamina,
visualizing binding between lamina tethered MeCP2G and
MeCP2R (Figure 2F upper row). As the majority of ectopic
fluorescently labeled MeCP2 was localized at the lamina, the
common heterochromatic foci of fluorescent MeCP2 were nearly
undetectable (Figure 2D and F). Besides, triple transfection of
GBP-laminB1, MBD2G or MeCP2G and MBD2R further
showed cells with clear co-localization of the RFP and GFP
signal, indicating in vivo binding of MBD2 to itself (Figure 2F
middle row) and of MBD2 to MeCP2 (Figure 2F lower row).
Using two independent in vivo assays, we clearly illustrate that
the observed direct associations between MeCP2 and MeCP2,
MeCP2 and MBD2 as well as MBD2 and MBD2 do also take
place in vivo and could be visualized in single cells.
Mapping Domains Responsible for MeCP2 and MBD2
Homo- and Hetero-interactions
After establishing that full-length MeCP2 and full-length MBD2
associate in vitro and in vivo, we asked, which domains could be
responsible for the observed interactions. For that reason, we
performed in vitro pull-down experiments with recombinant
proteins extracted from Sf9 insect cells using 1 M NaCl containing
lysis buffer to disrupt DNA binding of the proteins. After
incubation of full-length MeCP2R or MBD2R proteins with
equal amounts of GFP or YFP-labelled MeCP2 deletions
immobilized to GBP bound sepharose beads, the protein
complexes were separated by SDS-PAGE and analysed by western
blot using anti RFP. This mapping of MeCP2 domains responsible
for MeCP2 association to itself and to MBD2 revealed the region
spanning MeCP2 interdomain (ID) and TRD (ID-TRD, amino
acids 163–309) to directly interact with MeCP2R and MBD2R to
the strongest extent, whereas other MeCP2 domains showed very
weak to no binding (Figure 3A and Figure S3A). Subsequent
mapping of RFP/Cherry-labeled MBD2 domains to full-length
MeCP2G and MBD2G showed, that the NH2-terminal domain of
MBD2 (NTD, amino acids 1–152) exhibited strong binding to
both MeCP2 and MBD2. Binding to full-length MBD2 of those
domains of MBD2 located COOH-terminal to the NTD, was very
weak compared to the one of the NTD (Figure 3B and Figure
S3B).
In summary, our analyses showed MeCP2 ID-TRD and
MBD2 NTD as the important domains for MeCP2 and MBD2
homo- and hetero-interactions (Figure 3A and B). Consequently,
we addressed, whether the ID-TRD of MeCP2 alone binds to
the ID-TRD of MeCP2 and NTD of MBD2 and whether
MBD2 NTD alone preferentially associates with ID-TRD of
MeCP2 and NTD of MBD2. In vitro pull-down experiments
using Cherry/RFP-labeled ID-TRD or NTD and immobilized
GFP/YFP-fused domains of MeCP2 and MBD2 showed, that
ID-TRD exhibited the strongest binding to itself and MBD2
NTD compared to MeCP2 COOH-terminus and the region
comprising NH2-terminus plus MBD and MBD2 COOH-
terminus (amino acids 153–141) (Figure 3C and Figure S4A).
MBD2 NTD alone further showed the strongest affinity to the
ID-TRD of MeCP2 and the COOH-terminus of MBD2
(Figure 3C and Figure S4A). That MBD2 NTD interacted
with MBD2 COOH-terminus stronger than to the MBD2 NTD
domain itself suggested an additional head-to-tail aggregation.
In a subsequent step, we further tested whether the homo- and
hetero-associations of MeCP2 and MBD2 specific domains
could also be observed in vivo performing co-immunoprecipita-
tion analysis. For that, HEK 293 cells were co-transfected with
plasmids coding for RFP- and GFP-fused ID-TRD, MBD2
NTD and COOH-terminus. After lysis, the cell extract was
subjected to immunoprecipitation using GBP protein coupled to
beads. The protein complexes were then separated by SDS-
PAGE and analyzed by western blot using anti RFP antibody.
Whereas only low amount of the RFP-fused proteins could be
detected bound to the GFP alone control, we could observe
specific homo-interactions between RFP- and GFP-labeled ID-
TRD of MeCP2 as well as of MBD2 NTD (Figure 4A and
Figure S4B). Furthermore, in vivo associations between MeCP2
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ID-TRD and the NTD of MBD2 were evident. Whereas the
in vitro experiments (Figure 3C and Figure S4A) indicated an
interaction between the NTD and the COOH-terminus of
MBD2 that was more prominent than the homo-association of
MBD2 NTD, our co-immunoprecipitation analyses clearly
showed stronger binding of MBD2 NTD to itself than to the
COOH-terminus (Figure 4A and Figure S4B). To estimate the
strength of these interactions, we further repeated the co-
immunoprecipitation analyses using 200 mM NaCl containing
buffer and this time washed the protein complexes with buffer
supplemented with 300 mM NaCl (Figure S4C). Whereas
especially the homo-interaction between MBD2 NTD was still
detectable, no clear association was observed between ID-TRD
with itself as well as with the MBD2 NTD and the NTD and
COOH-terminus of MBD2.
Based on these interaction studies, we show that MeCP2
directly mediates interactions to itself and MBD2 via its ID-TRD.
We identified the NTD as the domain of MBD2 responsible for its
direct binding to MeCP2. The NTD of MBD2 is further capable
to form associations with full-length MBD2 (Figure 4B and C). We
can exclude that the observed interactions were bridged by DNA,
as extraction of all proteins was performed at 1 M NaCl lysis
conditions to disrupt potential protein-DNA association.
Our data favor a mechanism for MeCP2-induced interconnec-
tion of nucleosomes involving MeCP2 homo-associations, mostly
through the ID-TRD. Furthermore, hetero-association of MeCP2
with other chromatin-bound MBD proteins could cause and
stabilize MeCP2-mediated heterochromatin aggregation as can be
seen from the association between MeCP2 and MBD2 in vitro and
in vivo. We show both, MeCP2 direct binding to MBD2, as well as
the independent interaction of the ID-TRD of MeCP2 with full-
length MBD2 and MBD2 NTD. We also observed strong direct
binding of MBD2 with itself. The observed hetero-interactions of
MeCP2 and MBD2 further give rise to the assumption, that
a multitude of homo- and hetero-associations between the MBD
proteins could coordinate heterochromatin reorganization in vivo.
This is supported by the fact that, except for MBD3, all MBD
proteins are localized at pericentric heterochromatin and mostly
MBD2 and MeCP2 are capable of inducing dose-dependent
chromatin aggregation [7]. Functional redundancy between the
MBD proteins has been suggested based on the finding that
clustering of pericentric heterochromatin is maintained in
MeCP2-deficient mouse tissues [7]. Moreover, our findings could
suggest overlapping functions as a result of cross-interactions,
which in all probability mediate and stabilize chromatin aggrega-
tion.
It has recently been proposed that MeCP2 is organized into
a NH2-terminal part consisting of the MBD and its flanking
regions (amino acids 1–75; ID: amino acids 164–210) that exert
modulating and stabilizing effects on MBD DNA binding in vitro
[24]. The second unit is shown to be formed by TRD and the
CTD that can independently induce chromatin compaction and
intra-associations of nucleosomal arrays [24]. As a higher ratio
of TRD-CTD is required to induce chromatin clustering
comparable with full-length MeCP2 in vitro, synergy between
both units has been suggested to underlay full MeCP2 function
regarding DNA binding and chromatin clustering [24]. These
findings underscore the possibility that MeCP2 requires its
MBD domain to be able to accumulate at chromatin and to
induce a certain level of chromatin aggregation. The ID-TRD
domain could in addition - based on our experiments - exert
cross-linking potential, which might increase the overall
heterochromatin clustering ability of MeCP2. In this regard,
we have recently ectopically targeted to heterochromatin
a MeCP2 Rett mutant with a missense mutation within the
MBD and thus unable to bind methylated cytosines and could
observe a rescue of its heterochromatin clustering ability [21].
We propose that the function of the MBD proteins in shaping
chromatin higher order structure relies on multiple DNA,
chromatin, chromatin-protein interactions and homo- and
hetero-associations between MBDs further enhance this chro-
matin web.
Supporting Information
Figure S1 Overview of uncut gels and membranes for
Figure 1A, 1B, 1C and 1D. Input cell extract (I) and bound
fraction (B). Numbers on the marker bands indicate the protein
size in kilodalton (kD). Whole membranes and stained gels (CBB)
are shown in (A) for Figure 1A and in (B) for Figure 1B, 1C and
1D.
(EPS)
Figure S2 Overview of uncut membranes for Figure 2A,
2B and 2C. Input cell extract (I) and bound fraction (B). Lanes,
that were on the original blot not next to each other, were moved
together for facilitated understanding which is indicated by dashed
lines. Numbers on the marker bands indicate the protein size in
kilodalton (kD).
(EPS)
Figure S3 Overview of uncut gels and membranes for
Figure 3A and B. Input cell extract (I) and bound fraction (B).
Numbers on the marker bands indicate the protein size in
kilodalton (kD). Dashed lines indicate that membrane/gels were
assembled together, as they were originally not next to each other
or come from different membranes and/or gels. Uncut stained gels
(CBB) and membranes are shown in (A) for Figure 3A and in (B)
for Figure 3B.
(EPS)
Figure S4 Overview of uncut gels and membranes for
Figure 3C and Figure 4A: Protein domains responsible
for MeCP2 and MBD2 homo- and hetero-interaction.
Input cell extract (I) and bound fraction (B). Numbers on the
marker bands indicate the protein size in kilodalton (kD). Whole
stained gel (CBB) and membrane pictures are shown in (A) for
Figure 3C and in (B) for Figure 4A. Dashed lines indicate that
membrane/gels pieces were assembled together, as they were
originally not next to each other or come from different
membranes and/or gels. (C) Co-Immunoprecipitation analysis
was done as for Figure 4A (Figure S4B) with the exception, that
after co-immunoprecipitation, the protein complexes were washed
with buffer containing 300 mM NaCl. HEK293-EBNA cells were
co-transfected with plasmids coding for GFP- and RFP-tagged
domains of MeCP2 and MBD2 as well as GFP control. After cell
lysis using 200 mM NaCl containing buffer, co-immunoprecipi-
tation was performed by incubation of the cell extract with GBP-
bound beads. The immobilized protein complexes were washed
afterwards with buffer containing 300 mM NaCl. The immobi-
lized GFP-labeled proteins (B) used for the interaction assay were
visualized by western blot using anti GFP antibody. The input (I)
and the co-immunoprecipitated fraction (B) of the RFP-labeled
proteins were visualized through western blot using anti RFP
antibody. The input (I) represents 7% of the total reaction volume.
(EPS)
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